The global enzyme replacement therapy market was valued at USD 9,955.4 Million in 2019 and is projected to reach USD 16,362.2 Million by 2027, expanding at a CAGR of 6.8% during the forecast period. Enzyme replacement therapy (ERT) is one of the important medical treatments prescribed to provide the enzymes that are deficient in the body. It replenishes the deficient enzymes in the patient’s body either through the intravenous (IV) or oral routes of administration. The IV route is widely accepted by people, these drugs are easily and rapidly absorbed in the body. Enzyme deficiencies in body can hamper the metabolism of glycogen, which results in the accumulation of glycogen in tissue, bones, and cardiac muscle. Deficiency of enzyme can result in a life-changing or life-threatening conditions. Enzyme replacement therapy is used for the treatment of ailments such as Gaucher Disease, Fabry Disease, Pompe Disease, SCID, and MPS Disease. These diseases are genetic disorders and can be transferred from parents to their children, if both the parents suffer from the ailment. These diseases cannot be cured completely; however, they can be controlled by replacing the enzymes that are lacking in the human body.
In terms of route of administration, the enzyme replacement therapy market has been bifurcated into injectable agents and oral agents. Solid dosage form in enzyme replacement therapy are given through the oral route of administration to fulfil the enzyme deficiency in the body. Enzyme replacement therapy through oral route include the tablets dosage form containing the enzyme. These enzymes are administered to fulfil the enzyme deficiency in the patient’s body. Zavesca is the oral drug developed by Actelion Pharmaceuticals Ltd indicated for the treatment of Gaucher’s disease. The oral route is more convenient than the parenteral route, as these drugs are easy to store and transport. Moreover, tablets are premeasured doses, which eliminates the need for measuring the medicine. These factors are fuelling the growth of oral route of administration segment. Parenteral and oral medicines are available in market and are used for the treatment of ERT to treat diseases such as Gaucher’s diseases and Fabry diseases. Key players in the market are focused on developing drugs for both these routes of administration.
Increased Prevalence of Chronic Diseases
Increasing prevalence of chronic diseases and life-threatening lysosomal storage diseases such as Gaucher, Pompe, Fabry, and SCID is expected to boost the global enzyme replacement therapy market. Rising awareness among people about the availability of ERT is encouraging and driving the market growth.
Technological Advancement Leading to Adoption of Technologies
Growing technological advancements have led to the adoption of technologies, which has increased the focus of manufacturers on drug development processes and the development of innovative therapies. This, in turn, is expected to propel the market growth during the forecast period. High absorption rate and rapid drug delivery through parenteral route of administration is driving the demand for parenteral dosage. Increasing financial support for rare diseases (including lysosomal storage diseases) by government and non-governmental organizations (NGOs) is projected to boost the market.
On the basis of route of administration, the enzyme replacement therapy market has been divided into oral and parenteral. Parenteral and oral medicines are available in the market and are used for the treatment of ERT to treat diseases such as Gaucher’s diseases and Fabry diseases. Key players in the market are focused on developing drugs for these routes of administration. Solid dosage form in enzyme replacement therapy are given through the oral route of administration to fulfil the enzyme deficiency in the body. Enzyme replacement therapy through oral route which includes the tablets dosage form containing the enzyme. These enzymes are administered to fulfil the enzyme deficiency in the patient’s body. Zavesca is the oral drug developed by Actelion Pharmaceuticals Ltd indicated for the treatment of Gaucher’s disease. The oral route is more convenient than the parenteral route, as these drugs are easy to store and transport. Moreover, tablets are premeasured doses, which eliminates the need for measuring the medicine. These factors are fuelling the growth of oral route of administration segment.
Parenteral route of administration in enzyme replacement therapy are given through the intravenous (IV) route, which is a fast route of delivery and shows rapid absorption as compared to oral route of administration. High availability of a large variety of parenteral enzyme replacement therapy is driving the demand of parenteral ERT, thus making it highly preferred treatment type for EMT. Cerezyme (imiglucerase), VPRIV (velaglucerase alfa), and ELELYSO (taliglucerase alfa) are major drugs used for injections and providing treatment for Gaucher’s disease as injectable agents.
Based on therapeutic conditions, the enzyme replacement therapy market has been segmented into Gaucher’s diseases, Fabry disease, Pompe diseases, Severe Combined Immunodeficiency (SCID), Mucopolysaccharidosis (MPS) disease, and others. ERT is prescribed to treat several diseases, especially to people who have a particular enzyme deficiency. Increasing prevalence of such diseases is expected to drive the enzyme replacement therapy market.
In terms of regions, the market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a promising region for the market. It constituted a 31.1% share of the market in 2019. Asia Pacific held significant market share of 25.7% in 2019. Availability of technological advancements and awareness among people drive the market in North America, followed by Europe. A majority of manufacturers are focused on developing the enzyme replacement therapy for treating a number of diseases. This is expected to boost the market during the forecast period. The market in Asia Pacific is expected to grow at a significant pace due to increasing population and growing prevalence of chronic and rare diseases.
Some frequently asked quetions about this report!
Additional company profiles can be provided on request.
Yes, the report covers therapeutic condition specific information.
According to this Growth Market Reports report, the market from enzyme replacement is likely to register a CAGR of 6.8% during forecast period 2020-2027, with an anticipated valuation of USD 16,362.2 million by the end of the 2027.
In addition to market size (in USD Million), company Market Share (in % for base year 2019), other data such as COVID-19 Impact on the enzyme replacement market, Macro-economic factors are available in the final report.
The increasing plantation activities for fulfilling the accelerated demand for enzyme replacement is to drive the market growth.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
The market is expected to witness slight decline between 2019 and 2020 owing to the impact of COVID-19 pandemic on the enzyme replacement market.
The base year considered for the global enzyme replacement market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Hospitals, clinics are the key end-user that are driving the enzyme replacement market.
Major Manufactures include, Sanofi, Takeda Pharmaceutical Company Limited, BioMarin, AbbVie Inc, Alexion Pharmaceuticals, Inc., Horizon Therapeutics plc, RECORDATI S.p.A., PROTALIX BIOTHERAPEUTICS, INC., Allergan, Pfizer Inc., and Leadiant Biosciences, Ltd.
Some other reports from this category!